NCT00873730

Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain

A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 108 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to evaluate efficacy and safety of etanercept 100 mg (50 mg twice a week) compared with 50 mg once a week in adult subjects with ankylosing spondylitis (AS) and previous failure to usual practice therapies in Spain.

Conditions

• Ankylosing Spondylitis

Interventions

Type	Name	Description
DRUG	etanercept	Etanercept 50 mg twice a week (BIW) for 12 weeks
DRUG	etanercept/placebo	Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks

Timeline

• Start date: 2006-12-01
• Primary completion: 2008-06-01
• Completion: 2008-06-01
• First posted: 2009-04-02
• Last updated: 2010-04-28
• Results posted: 2009-08-13